Next Article in Journal
Recent Advances in the Use of Plant Virus-Like Particles as Vaccines
Previous Article in Journal
Molecular Epidemiology of HIV-1 Infected Migrants Followed Up in Portugal: Trends between 2001–2017
Article

A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome

1
Division of Infectious Diseases, IRCCS, Ospedale San Raffaele, 20132 Milan, Italy
2
Ordine dei Medici della Valle d’Aosta, 11100 Aosta, Italy
3
Department of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milan, Italy
4
Vita-Salute San Raffaele University, 20132 Milan, Italy
*
Author to whom correspondence should be addressed.
Viruses 2020, 12(3), 269; https://doi.org/10.3390/v12030269
Received: 27 November 2019 / Revised: 24 February 2020 / Accepted: 26 February 2020 / Published: 28 February 2020
(This article belongs to the Section Viral Immunology, Vaccines, and Antivirals)
We prospectively evaluated the frequency of natural resistance-associated substitutions (RASs) in the NS3 and NS5A regions according to different HCV genotypes and their possible effect on treatment outcome in HIV-1/HCV patients treated with direct-acting antivirals (DAAs). Baseline RASs in the NS3 and NS5A domains were investigated in 62 HIV-1/HCV patients treated with DAAs: 23 patients harbored HCV-GT1a, 26 harbored GT3a, and 13 harbored GT4d. A higher occurrence of RASs was found in the NS3 domain within GT1a (13/23) than GT3a (0/26) or GT4d (2/13). With regard to treatment outcome, NS3 RASs were detected in 14/56 patients with sustained virological response (SVR) and in 1/6 non-responder (NR) patients. Occurrence of RASs of NS5A domain was lower in SVR (4/56, had RASs) than in NR (3/6, had RASs). Evaluation of RASs at baseline instead of at virological failure, especially in the NS5A domain, could positively influence the choice of new DAA combinations for the treatment of HIV-1/HCV patients. View Full-Text
Keywords: HCV resistance; genotype; HIV-1; direct acting antivirals HCV resistance; genotype; HIV-1; direct acting antivirals
Show Figures

Figure 1

MDPI and ACS Style

Bagaglio, S.; Hasson, H.; Peano, L.; Vercesi, R.; Messina, E.; Galli, A.; Uberti-Foppa, C.; Morsica, G. A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome. Viruses 2020, 12, 269. https://doi.org/10.3390/v12030269

AMA Style

Bagaglio S, Hasson H, Peano L, Vercesi R, Messina E, Galli A, Uberti-Foppa C, Morsica G. A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome. Viruses. 2020; 12(3):269. https://doi.org/10.3390/v12030269

Chicago/Turabian Style

Bagaglio, Sabrina, Hamid Hasson, Luca Peano, Riccardo Vercesi, Emanuela Messina, Andrea Galli, Caterina Uberti-Foppa, and Giulia Morsica. 2020. "A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome" Viruses 12, no. 3: 269. https://doi.org/10.3390/v12030269

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop